Clinical Trial Update: A Panobinostat Presurgery [Phase 2]

View source ↗

Summary

A presurgical Phase 2 trial of panobinostat for recurrent glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Duke University | Conditions: Recurrent Glioblastoma | Phase 2 | Status: WITHDRAWN